Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharma has the GF Score of 40, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Oncolys BioPharma
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Oncolys BioPharma (TSE:4588) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Oncolys BioPharma GF Score Related Terms
TSE:4588 vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, Oncolys BioPharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's GF Score distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's GF Score falls into.
Oncolys BioPharma (TSE:4588) has a GF Score of 40 as of Jul. 16, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Oncolys BioPharma and its competitors. This is 29% below median its historical median of 56.00. Over the past decade, Oncolys BioPharma's GF Score has ranged from 9.00 to 79.00.
Is Oncolys BioPharma's GF Score too high?
Oncolys BioPharma's current GF Score of 40 is 29% below median its 10-year median of 56.00. Over the past 10 years, this metric has ranged from a low of 9.00 to a high of 79.00. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's GF Score compare to VRTX and REGN?
Oncolys BioPharma's GF Score of 40 can be compared against companies in the Biotechnology industry. Historically, Oncolys BioPharma's own GF Score has ranged from 9.00 to 79.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current GF Score is 40, which is 29% below median its own 10-year median of 56.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円362.88, compared to a current price of 円2,620.00 — trading 622% above its estimated fair value. The current GF Score is 40, which is 29% below median its 10-year median of 56.00. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current GF Score is 40 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,620.00 is trading 622% above its estimated GF Value™ of 円362.88.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
GF Score: 40 (29% below median its 10-year median of 56.00)
GF Value™: 円362.88 vs. price of 円2,620.00 (622% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
